Developing Lactoferrin and New Materials Through NRLファーマ
First written in FY2018-Q1. 14 of 33 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-09-24.
No other company in this theme has enough history to compare yet.
- 2026-09-24Advancednews.nicovideo.jp
「The agreement formally establishes a framework for cooperation between the two companies and is intended to define the details of joint research, including the development and evaluation of materials and technical exchanges.」
The framework for joint research into new functional materials, including development, evaluation and technical exchanges, has reportedly been formally established. - FY2026AdvancedAnnual report
「On 1 April 2026, ㈱NRLファーマ, which had operated the business, was absorbed into 日本予防医薬㈱ in a merger.」
The functional materials development function of NRL Pharma was consolidated into 日本予防医薬 through an absorption-type merger, consolidating the materials development and sales functions. - FY2026-H1AdvancedAnnual report
「During the current interim consolidated accounting period, revenue remained roughly in line with the same period of the previous year, supported in part by steady sales of existing OEM products and orders related to femtech. However, the operating margin improved substantially as a result of fixed-cost reductions from structural reforms. As a result, the functional materials development business reported revenue of ¥170 million, down 1.0% year on year, and operating profit of ¥18 million, up 482.2% year on year.」
Steady sales of existing OEM products and orders related to femtech, together with fixed-cost reductions from structural reforms, resulted in operating profit of ¥18 million, up 482.2% year on year. Improved profitability in the functional materials and femtech-related businesses is taking concrete shape. - FY2025Strong femtech orders but sluggish raw-material salesAnnual report
「During the current consolidated fiscal year, new orders for OEM products related to femtech were strong, but raw-material sales remained sluggish, resulting in a decline in revenue.」
While new orders for OEM products related to femtech were strong, sluggish sales of lactoferrin raw materials and investment in research and development resulted in lower revenue and an operating loss for the functional materials development business. - FY2025-H1AdvancedAnnual report
「During the current interim consolidated accounting period, raw-material sales volume remained at the same level as in the same period of the previous year, while revenue increased due in part to strong sales of existing OEM products and new orders related to femtech. As a result, the functional materials development business reported revenue of ¥172 million, up 10.0% year on year, and operating profit of ¥3 million, compared with an operating loss of ¥0 million in the same period of the previous year.」
Strong new orders related to femtech, in addition to existing OEM products, resulted in higher revenue for the functional materials development business and a shift from an operating loss to an operating profit. Progress in the rollout of new materials and products is being reflected in orders and profit. - FY2024AdvancedAnnual report
「On 1 November 2023, additional shares of ㈱NRLファーマ were acquired, raising the voting rights ratio to 98.7%.」
Additional shares of NRL Pharma were acquired, raising the voting rights ratio to 98.7%. The Group's involvement in the functional materials development business, including lactoferrin, increased. - FY2024-Q3Continued operating loss due to sluggish raw-material sales volumeAnnual report
「During the cumulative third quarter of the current consolidated fiscal period, sales of supplements containing lactoferrin and other ingredients were strong, but revenue declined due in part to sluggish sales volume of raw materials. As a result, the functional materials development business reported revenue of ¥242 million, down 36.3% year on year, and an operating loss of ¥0 million, compared with an operating profit of ¥43 million in the same period of the previous year.」
While sales of supplements containing lactoferrin remained strong, sluggish sales volume of raw materials resulted in a decline in revenue, and the business has continued to be in a position where it moved from an operating profit in the same period of the previous year to an operating loss. - FY2024-Q2Slipped into an operating loss due to sluggish sales volumeAnnual report
「During the cumulative second quarter of the current consolidated fiscal period, sales of supplements containing lactoferrin and other ingredients were strong, but revenue declined due in part to sluggish sales volume of raw materials. As a result, the functional materials development business reported revenue of ¥156 million, down 43.3% year on year, and an operating loss of ¥0 million, compared with an operating profit of ¥42 million in the same period of the previous year.」
While sales of supplements containing lactoferrin remained strong, sluggish sales volume of raw materials resulted in a substantial decline in revenue, and the business moved from an operating profit in the same period of the previous year to an operating loss. - FY2024-Q1Continued lower revenue and lower operating income due to sluggish sales volumesAnnual report
「During the first quarter of the fiscal year under review, sales of supplements containing lactoferrin and other ingredients were strong, but sales volumes of raw materials remained sluggish, among other factors, resulting in lower revenue. As a result, the functional materials development business reported revenue of ¥67 million, down 51.0% year on year, and an operating loss of ¥7 million, compared with operating income of ¥22 million in the same quarter of the previous year.」
While supplement sales remained strong, sluggish growth in sales volume of lactoferrin raw materials resulted in a substantial decline in revenue for the functional materials development business, which moved from an operating profit in the same period of the previous year to an operating loss. - FY2023Continued full-year lower revenue and lower operating income due to sluggish sales volumesAnnual report
「During the fiscal year under review, revenue continued to trend downward, partly because sales volumes of lactoferrin raw materials remained sluggish. As a result, the functional materials development business reported revenue of ¥489 million, down 12.3% year on year, and operating income of ¥42 million, down 48.7% year on year.」
Due to sluggish sales volumes of lactoferrin raw materials, the functional materials development business reported lower revenue and lower operating income for the full year. - FY2023-Q2Continued lower revenue and lower operating income due to sluggish sales volumesAnnual report
「During the second quarter of the fiscal year under review, revenue continued to trend downward, partly because sales volumes of lactoferrin raw materials remained sluggish. As a result, the functional materials development business reported revenue of ¥276 million, down 22.7% year on year, and operating income of ¥42 million, down 32.4% year on year.」
Due to sluggish sales volumes of lactoferrin raw materials, the functional materials development business reported lower revenue and lower operating income for the second consecutive quarter. - FY2023-Q1Lower revenue and lower operating income due to sluggish sales volumesAnnual report
「During the first quarter of the fiscal year under review, revenue continued to trend downward, partly because sales volumes of lactoferrin raw materials remained sluggish. As a result, the functional materials development business reported revenue of ¥137 million, down 23.9% year on year, and operating income of ¥22 million, down 34.4% year on year.」
Due to sluggish sales volumes of lactoferrin raw materials, the functional materials development business reported lower revenue and lower operating income. It shifted to a weaker trend from the higher revenue and higher operating income generated by raw material sales in the previous fiscal year. - FY2022-Q3Continued lower revenue and lower operating income due to sluggish sales volumesAnnual report
「During the third quarter of the fiscal year under review, revenue continued to trend downward, partly because sales volumes of lactoferrin raw materials remained sluggish. As a result, the functional materials development business reported revenue of ¥467 million, down 26.7% year on year, and operating income of ¥75 million, down 49.3% year on year.」
Due to sluggish sales volumes of lactoferrin raw materials, the functional materials development business reported lower revenue and lower operating income for the second consecutive quarter. - FY2022-Q2Lower revenue and lower operating income due to sluggish sales volumesAnnual report
「During the second quarter of the fiscal year under review, revenue continued to trend downward, partly because sales volumes of lactoferrin raw materials remained sluggish. As a result, the functional materials development business reported revenue of ¥357 million, down 23.1% year on year, and operating income of ¥63 million, down 47.7% year on year.」
Due to sluggish sales volumes of lactoferrin raw materials, the functional materials development business reported lower revenue and lower operating income than in the same period of the previous year. Results shifted from the higher revenue and higher operating income reported through the previous quarter to lower revenue and lower operating income. - FY2022-Q1Lower revenue and profitAnnual report
「During the first quarter of the fiscal year under review, revenue continued to trend downward, partly because sales volumes of lactoferrin raw materials remained sluggish. As a result, the functional materials development business reported revenue of ¥180 million, down 30.2% year on year, and operating income of ¥34 million, down 53.2% year on year.」
The functional materials development business reported lower revenue and lower operating income due to sluggish sales volumes of lactoferrin raw materials. - FY2021-Q3AdvancedAnnual report
「During the third quarter of the fiscal year under review, sales of lactoferrin raw materials continued to trend upward, primarily due to higher raw material prices and increased delivery volumes. As a result, the functional materials development business reported revenue of ¥637 million, up 23.5% year on year, and operating income of ¥148 million, up 131.9% year on year.」
Against a backdrop of higher lactoferrin raw material prices and increased delivery volumes, the functional materials development business reported revenue of ¥637 million and operating income of ¥148 million, achieving higher revenue and higher operating income than in the same period of the previous year. - FY2021-Q1AdvancedAnnual report
「As a result, the functional materials development business reported revenue of ¥259 million, up 61.4% year on year, and operating income of ¥73 million, up 210.3% year on year.」
The functional materials development business reported higher revenue and higher operating income, driven by higher prices for lactoferrin raw materials and an increase in delivery volumes, generating revenue of ¥259 million and operating income of ¥73 million. - FY2020Full-year revenue and profit declineAnnual report
「As a result, partly due to the impact of the change in the fiscal year-end of a consolidated subsidiary in the previous fiscal year, the functional materials development business reported full-year revenue of ¥730 million, down 14.1% year on year, and operating income of ¥99 million, down 37.3% year on year.」
Although sales of lactoferrin raw materials and patent licensing income were recorded, the business reported lower revenue and lower operating income for the full year, partly due to the impact of the change in the fiscal year-end. - FY2020-Q3Lower revenue and profitAnnual report
「During the third quarter of the fiscal year under review, revenue included sales of lactoferrin raw materials and licensing income from licensing patents related to enteric coating technology for lactoferrin and its use to improve lipid metabolism. As a result, partly due to the impact of the change in the fiscal year-end of a consolidated subsidiary in the previous fiscal year, the functional materials development business reported revenue of ¥515 million, down 26.2% year on year, and operating income of ¥64 million, down 54.8% year on year.」
Although sales of lactoferrin raw materials and patent licensing income were recorded, the functional materials development business reported lower revenue and lower operating income year on year, partly due to the impact of the change in the fiscal year-end. - FY2020-Q2Lower revenue and profitAnnual report
「As a result, partly due to the impact of the change in the fiscal year-end of a consolidated subsidiary in the previous fiscal year, the functional materials development business reported revenue of ¥342 million, down 33.1% year on year, and operating income of ¥45 million, down 54.3% year on year.」
The functional materials development business, including sales of lactoferrin raw materials and licensing income from related patents, reported lower revenue and lower operating income year on year. - FY2019AdvancedAnnual report
「As a result, partly due to the impact of a change in the fiscal year-end of a consolidated subsidiary, the functional materials development business reported revenue of ¥850 million, up 29.9% year on year, and operating income of ¥159 million, up 150.4% year on year.」
The functional materials development business, including sales of lactoferrin raw materials and licensing income from related patents, achieved higher revenue and higher operating income for the full year. Revenue was ¥850 million and operating income was ¥159 million, reflecting an expansion in business results from the previous fiscal year. - FY2019-Q3AdvancedAnnual report
「As a result, partly due to the impact of a change in the fiscal year-end of a consolidated subsidiary, the functional materials development business reported revenue of ¥699 million, up 39.6% year on year, and operating income of ¥142 million, up 168.8% year on year.」
The functional materials development business, including sales of lactoferrin raw materials and licensing income from related patents, reported revenue of ¥699 million and operating income of ¥142 million, representing continued growth in both revenue and operating income. - FY2019-Q2AdvancedAnnual report
「As a result, partly due to the impact of a change in the fiscal year-end of a consolidated subsidiary, the functional materials development business reported revenue of ¥511 million, up 86.4% year on year, and operating income of ¥100 million, compared with an operating loss of ¥7 million in the same period of the previous year.」
The functional materials development business, including sales of lactoferrin raw materials and licensing income from related patents, recorded higher revenue and higher operating income, moving from an operating loss in the same period of the previous year to operating income. - FY2019-Q1AdvancedAnnual report
「As a result, partly due to the impact of a change in the fiscal year-end of a consolidated subsidiary, the functional materials development business reported revenue of ¥324 million, up 93.4% year on year, and operating income of ¥54 million, compared with an operating loss of ¥2 million in the same period of the previous year.」
The functional materials development business, including sales of lactoferrin raw materials and licensing income from related patents, recorded revenue of ¥324 million and operating income of ¥54 million, moving from an operating loss in the same period of the previous year to operating income. In addition, 6 months of NRL Pharma's results were consolidated following the change in its fiscal year-end. - FY2018AdvancedAnnual report
「During the fiscal year under review, revenue included sales of lactoferrin raw materials and licensing income from licensing patents related to enteric coating technology for lactoferrin and its use to improve lipid metabolism. As a result, the functional materials development business reported revenue of ¥655 million and operating income of ¥63 million.」
The income statement of NRL Pharma was consolidated, and the functional materials development business, including sales of lactoferrin raw materials and patent licensing, recorded revenue of ¥655 million and operating income of ¥63 million. - FY2018-Q3AdvancedAnnual report
「During the third quarter of the fiscal year under review, revenue included sales of lactoferrin raw materials and licensing income from licensing patents related to enteric coating technology for lactoferrin and its use to improve lipid metabolism. As a result, the functional materials development business reported revenue of ¥500 million and operating income of ¥52 million.」
Sales of lactoferrin raw materials and licensing income from related patents were recorded, resulting in revenue of ¥500 million and operating income of ¥52 million for the functional materials development business. The business progressed from an operating loss in the previous quarter to operating income. - FY2018-Q2AdvancedAnnual report
「During the second quarter of the fiscal year under review, revenue included sales of lactoferrin raw materials and licensing income from licensing patents related to enteric coating technology for lactoferrin and its use to improve lipid metabolism. As a result, the functional materials development business reported revenue of ¥274 million and an operating loss of ¥7 million.」
The functional materials development business, including NRL Pharma, recorded sales of lactoferrin raw materials and licensing income from related patents, generating revenue of ¥274 million. The development and sale of materials and the utilisation of intellectual property are reflected in specific business results. - FY2018-Q1First statedAnnual report
「In June 2017, we made NRL Pharma Co., Ltd., whose business consists of developing and selling functional materials centred on lactoferrin, a consolidated subsidiary. Going forward, the Group plans to develop new products using lactoferrin in its cosmetics and health supplement businesses, while also actively pursuing the development of new materials by leveraging synergies with the company.」
In June 2017, NRL Pharma became a consolidated subsidiary, and the company first stated its policy of using lactoferrin in new cosmetics and health supplement products and pursuing the development of new materials through synergies with the company.